Ā | Non-ESBL (n=45) | ESBL (n=52) | P-value |
---|---|---|---|
Sex (M:F) | 26:19 | 27:25 | 0.334 |
MeanāĀ±āSD of age (month) | 65āĀ±ā81 | 69āĀ±ā75 | 0.708 |
MeanāĀ±āSD of length of stay | 37āĀ±ā57 | 93āĀ±ā180 | 0.083 |
Day | 25 | 40 | <ā0.01 |
Underlying disease | |||
Ā Hematological malignancy | 8 | 15 | 0.463 |
Ā Solid tumor | 2 | 2 | 0.661 |
Ā Nephrotic syndrome | 2 | 3 | 1 |
Ā Congenital heart disease | 1 | 12 | <ā0.01 |
Ā End stage renal disease | 3 | 3 | 0.661 |
Ā SLE | 0 | 2 | 0.497 |
Ā Preterm | 7 | 0 | <ā0.01 |
Ā Newborn | 2 | 1 | 0.595 |
Ā Chronic lung disease | 0 | 2 | 0.497 |
Ā Neurological problem | 4 | 4 | 0.729 |
Focal infection | |||
Ā Pneumonia | 10 | 21 | 0.17 |
Ā Urinary tract infection | 13 | 14 | 0.58 |
Ā Diarrhea | 1 | 5 | 0.18 |
Ā Cellulitis | 1 | 3 | 0.54 |
Ā Ascending cholangitis | 2 | 0 | 0.15 |
Ā Meningitis | 2 | 2 | 0.72 |
Mortality (%) | 6 (13.3%) | 20 (38.9%) | <ā0.05 |